Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16143070 | 0.83 | NOTUM (0.56) | CNR1CNR2NPC1RAB9AATM | |
| SCHEMBL9119278 | 0.79 | CNR1 (0.55) | CNR1CNR2NPC1RAB9AATM | |
| SCHEMBL18496587 | 0.75 | HTT (0.55) | NPC1RAB9AATMGAAALDH1A1 | |
| SCHEMBL18285279 | 0.73 | CNR2 (0.45) | CNR1CNR2NPC1RAB9AATM | |
| SCHEMBL29727678 | 0.73 | CNR2 (0.45) | CNR1CNR2NPC1RAB9AATM | |
| SCHEMBL26473968 | 0.73 | CES2 (0.50) | GAACES2TRPV1NOTUM | |
| SCHEMBL20877084 | 0.73 | CES2 (0.55) | GAACES2TACR1HDAC3HDAC8 | |
| SCHEMBL16261257 | 0.72 | ADCY8 (0.43) | GAACES2TACR1DDR1NOTUM | |
| SCHEMBL3606497 | 0.72 | NOTUM (0.66) | CNR1GAACES2NOTUMALDH1A1 | |
| SCHEMBL18077883 | 0.72 | HDAC3 (0.42) | NPC1RAB9AHDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1152877-C | Piperazine derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| CN-1334812-A | Piperazine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | CNR1 388/4885CNR2 344/4885NPC1 1055/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | CNR1 636/4885CNR2 404/4885NPC1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.